Trial · NCT00559962

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

NCT00559962, Phase 2, Completed, Aegerion Pharmaceuticals, Inc.; results first posted 2013-02-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS. Trials, record NCT00559962. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00559962

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
NCT number: NCT00559962
Status: Completed
Phases: Phase 2
Enrollment: 260 participants, actual
Lead sponsor: Aegerion Pharmaceuticals, Inc.
Conditions: Hyperlipidemia
Interventions: AEGR-733, placebo, AEGR-733, AEGR-733, AEGR-733, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe
First posted: 2007-11-19
Last updated: 2018-02-23
Results first posted: 2013-02-22

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Absolute Change From Baseline in Percent Hepatic Fat	Baseline and 12 weeks on study drug	Absolute change from Baseline in percent hepatic fat
Secondary	Absolute Change From Baseline in Percent Hepatic Fat	Baseline and 12 weeks on study drug	Absolute change from Baseline in percent hepatic fat

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Absolute Change From Baseline in Percent Hepatic Fat	Baseline and 12 weeks on study drug	ITT	Percent of Hepatic Fat	MEAN
SECONDARY	Absolute Change From Baseline in Percent Hepatic Fat	Baseline and 12 weeks on study drug	ITT	Percent of Hepatic Fat	MEAN

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Absolute Change From Baseline in Percent Hepatic Fat	Placebo	0.03	Standard Deviation 1.814	Percent of Hepatic Fat
Absolute Change From Baseline in Percent Hepatic Fat	AEGR-733 5 mg	4.72	Standard Deviation 6.297	Percent of Hepatic Fat
Absolute Change From Baseline in Percent Hepatic Fat	Placebo	0.03	Standard Deviation 1.814	Percent of Hepatic Fat
Absolute Change From Baseline in Percent Hepatic Fat	AEGR-733 2.5 mg	4.95	Standard Deviation 7.122	Percent of Hepatic Fat
Absolute Change From Baseline in Percent Hepatic Fat	AEGR-733 5 mg	4.72	Standard Deviation 6.297	Percent of Hepatic Fat
Absolute Change From Baseline in Percent Hepatic Fat	AEGR-733 7.5 mg	3.94	Standard Deviation 5.763	Percent of Hepatic Fat
Absolute Change From Baseline in Percent Hepatic Fat	AEGR-733 10 mg	7.86	Standard Deviation 9.515	Percent of Hepatic Fat
Absolute Change From Baseline in Percent Hepatic Fat	AEGR-733 5 mg + Atorvastatin 20 mg	3.68	Standard Deviation 5.365	Percent of Hepatic Fat
Absolute Change From Baseline in Percent Hepatic Fat	AEGR-733 5 mg + Fenofibrate 145 mg	7.70	Standard Deviation 9.390	Percent of Hepatic Fat
Absolute Change From Baseline in Percent Hepatic Fat	AEGR-733 5 mg + Ezetimibe 10 mg	7.55	Standard Deviation 6.230	Percent of Hepatic Fat

Source ClinicalTrials.gov

Participant flow24

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	33
Overall Study	STARTED	AEGR-733 2.5 mg	34
Overall Study	STARTED	AEGR-733 5 mg	34
Overall Study	STARTED	AEGR-733 7.5 mg	34
Overall Study	STARTED	AEGR-733 10 mg	35
Overall Study	STARTED	AEGR-733 5 mg + Atorvastatin 20 mg	28
Overall Study	STARTED	AEGR-733 5 mg + Fenofibrate 145 mg	33
Overall Study	STARTED	AEGR-733 5 mg + Ezetimibe 10 mg	29
Overall Study	COMPLETED	Placebo	31
Overall Study	COMPLETED	AEGR-733 2.5 mg	25

1 to 10 of 24Source ClinicalTrials.gov

See all 24 participant flow

Adverse events312

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Diarrhoea	Gastrointestinal disorders	Placebo	4	33
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 2.5 mg	16	34
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 5 mg	15	34
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 7.5 mg	16	34
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 10 mg	23	35
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 5 mg + Atorvastatin 20 mg	14	28
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 5 mg + Fenofibrate 145 mg	15	33
other	Diarrhoea	Gastrointestinal disorders	AEGR-733 5 mg + Ezetimibe 10 mg	19	29
other	Nausea	Gastrointestinal disorders	Placebo	1	33
other	Nausea	Gastrointestinal disorders	AEGR-733 2.5 mg	2	34

1 to 10 of 312Source ClinicalTrials.gov

See all 312 adverse events

Adverse event totals24

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	AEGR-733 2.5 mg
Total, all-cause mortality	AEGR-733 5 mg
Total, all-cause mortality	AEGR-733 7.5 mg
Total, all-cause mortality	AEGR-733 10 mg
Total, all-cause mortality	AEGR-733 5 mg + Atorvastatin 20 mg
Total, all-cause mortality	AEGR-733 5 mg + Fenofibrate 145 mg
Total, all-cause mortality	AEGR-733 5 mg + Ezetimibe 10 mg
Total, other adverse events	Placebo	20	33
Total, other adverse events	AEGR-733 2.5 mg	31	34

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00559962

GET https://conductscience.org/api/trials/v1/NCT00559962/flow?page=2

API reference For AI assistants